Company Legal Name
Latest Valuation
Founded Year
Headquarter
HistoSonics Inc. develops advanced medical devices that non-invasively destroy tumors using focused ultrasound technology combined with real-time imaging guidance. Based in Plymouth, United States, the company specializes in histotripsy, a precise therapeutic approach that mechanically breaks down targeted tissue without thermal damage to surrounding healthy areas. This innovative platform offers physicians a minimally invasive alternative to traditional surgical procedures and radiation therapy for tumor treatment. HistoSonics' technology represents a significant advancement in non-invasive oncology treatments, positioning the company at the forefront of next-generation therapeutic ultrasound solutions for cancer care applications.
Available in most regions; subject to local regulations.
Open to non-accredited investors with KYC/AML compliance. U.S. investors must meet SEC requirements.
$10 per token, enabling fractionalized access to Pre-IPO shares.
Mandatory identity (KYC) and proof of funds checks.
Variable, applied to investment amounts.
Charged on realized profits.
Tokens may be locked for 6–12 months; resale depends on secondary market liquidity.
Prices reflect past funding rounds, not guaranteed future value.
Biotech depends on regulatory approvals; fintech faces evolving digital asset rules.
Blockchain or custodian issues could delay transfers or verification.
Changing laws may affect tradability or taxation.
